North America – Page 12 – pharmaceutical daily

December 10, 2021 Off

Medicago, GSK report primary and secondary endpoints with available data met in trial dominated by COVID-19 variants

Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announce positive efficacy and safety results from the global Phase 3 placebo-controlled efficacy study of Medicago’s plant-based COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant, conducted in over 24,000 subjects, adults 18y and above, across six countries.

December 8, 2021 Off

New finding shows that Pfizer’s Covid-19 vaccine can partially protect from the Omicron variant of the virus

By Dino Mustafić

New finding shows that Pfizer’s Covid-19 vaccine can partially protect from the Omicron variant of the virus.

December 7, 2021 Off

Medicago and GSK receive good news for its plant-based COVID-19 vaccine candidate

By Dino Mustafić

Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) have received positive efficacy and safety results from the global Phase 3 placebo-controlled efficacy study of Medicago’s plant-based COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant, conducted in over 24,000 subjects, adults 18 years and above, across six countries.

October 12, 2021 Off

Hikma launches Micafungin for Injection

By Dino Mustafić

Hikma Pharmaceuticals has announced it launched Micafungin for Injection through its US affiliate, Hikma Pharmaceuticals USA Inc. The company has launched 50mg and 100mg doses.

October 5, 2021 Off

Merck to seek emergency use authorization for Molnupiravir, oral antiviral medicine for COVID-19

By Dino Mustafić

The drug maker Merck said it plans to seek emergency use authorization in the U.S. as soon as possible and to submit applications to regulatory agencies worldwide for Molnupiravir, which could be the first oral antiviral medicine for COVID-19.

September 20, 2021 Off

Cellbox Solutions kicks off subsidiary in the USA

By Dino Mustafić

Cellbox Solutions GmbH, developer of the patented Cellbox technology, has founded their U.S. company and is now selling products directly to the U.S./North American market.

July 23, 2021 Off

Pfizer and BioNTech to Provide U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.

By BusinessWire

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. government has purchased an additional 200 million doses of the Pfizer-BioNTech COVID-19 Vaccine.

July 23, 2021 Off

Moderna Announces Establishment of New Charitable Foundation

By BusinessWire

Initial up-front endowment of $50 million Foundation to support charitable organizations and causes that promote public health, healthcare and educational…

July 19, 2021 Off

Merck Announces U.S. FDA Approval of VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Adults 18 Years and Older Caused by 15 Serotypes

By BusinessWire

Clinical Data Supporting Approval Demonstrated Non-Inferior Immune Responses for the Serotypes Shared with PCV13 (1, 3, 4, 5, 6A, 6B,…

July 16, 2021 Off

Corvus Pharmaceuticals Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations

By GlobeNewswire

Mupadolimab Phase 1/1b oncology clinical trial continues, with a focus on leveraging B cell activation and enhancement of anti-viral antibodies…